Drug Profile
SOA 132
Alternative Names: F 1322; SOA-132Latest Information Update: 13 Dec 2018
Price :
$50
*
At a glance
- Originator UCB Japan
- Developer Sosei Heptares
- Class Antiasthmatics
- Mechanism of Action 5-lipoxygenase inhibitors; Histamine receptor antagonists; Mast cell stabilisers; Thromboxane synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Asthma; Hypersensitivity
Most Recent Events
- 03 Dec 2018 Heptares Therapeutics has merged with Sosei to form Sosei Heptares
- 18 Jul 2007 Discontinued - Preclinical for Allergy in Japan (Intranasal)
- 18 Jul 2007 Discontinued - Preclinical for Asthma in Japan (Inhalation)